相关实验视频

Updated: May 20, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

针对HuR/E2F7轴与博尔特佐米布对抗多发性骨髓瘤的协同作用

Ming-Yuan Jia¹, Chao Wu², Ze Fu¹

¹Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Acta pharmacologica Sinica

|March 26, 2025

概括

准人类抗原R (HuR) 和其下游分子E2F7显示出治疗多发性骨髓瘤 (MM) 的前景. 这种方法与博尔特佐米布结合,为这种无法治愈的血液癌症提供了一种新的治疗策略.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

多发性骨髓瘤 (MM) 是一种无法治愈的血细胞恶性瘤,经常复发和耐药.
人类抗原R (HuR) 与瘤进展有关,但其在MM中的作用尚不清楚.
新的治疗目标对于改善MM治疗结果至关重要.

研究的目的:

调查HuR在MM病变发生中的作用及其作为治疗点的潜力.
在MM中识别由HuR调节的下游分子.
为了评估向HuR/E2F7轴在MM治疗中与博特佐米布结合使用的疗效.

主要方法:

对公共数据集的分析,以评估MM患者的HuR表达和预后意义.
在体外和体内研究中,使用短毛RNA (shRNA) 和HuR抑制剂CMLD-2.
RNA测序以识别HuR下游目标.
使用CMLD-2和博特佐米布进行组合治疗的研究.

主要成果:

在MM患者中,HuR的表达很高,与预后不佳相关.
向HuR抑制了MM细胞的增殖,并增强了博特佐米布的敏感性.
通过稳定其mRNA,HuR通过上调调节E2F7表达,而高E2F7水平与预后不佳有关.
抑制HuR/E2F7轴与博特佐米布协同作用,在体外和体内都显示出显著的抗MM作用.

结论:

在MM的进展中,HuR/E2F7轴起着至关重要的作用.
针对HuR,特别是与博尔特佐米布结合,是MM的有前途的治疗策略.
华尔/E2F7轴是克服MM药物耐药性的潜在治疗目标.

关键词:

在CMLD-2中使用.E2F7 E2F7 E2F7 E2F7 E2F7 E2F7 E2F7 E2F7 这就是 HuRR 的意思.博尔特佐米布 (Bortezomib) 是一种药物.多发性骨髓瘤是多发性骨髓瘤的一种疾病.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...